SCOTT ARTHUR WALDMAN, MD, PhD, FCP, FAHA, FNAI, FASPET
`CURRICULUM VITAE
`
`CURRENT POSITIONS {Thomas Jefferson University)
`
`Chair, Department of Pharmacology, Physiology and Cancer Biology
`Samuel MV Hamilton Professor of Medicine
`Director, MD-PhD Program
`Sidney Kimmel Medical College
`
`ADDRESS
`
`Department of Pharmacology, Physiology and Cancer Biology
`Thomas Jefferson University
`132 South 10th Street
`1170 Main
`Philadelphia, Pennsylvania 19107
`
`PERSONAL
`
`October 22, 1953
`Date of Birth:
`Brooklyn, New York
`Place of Birth:
`Marital Status: Married 1975, 2 Children
`
`EDUCATION
`
`Stanford University, Palo Alto, California
`School of Medicine: 1983-1987
`M .D. conferred June, 1987
`
`Thomas Jefferson University, Philadelphia, Pennsylvania
`Department of Anatomy, School of Medicine: 1975-1979
`Ph.D. conferred June, 1980
`Majors: Human Anatomy, Biochemistry
`M inor: Developmenta l Biology
`
`State University of New York at Albany, Albany, New York: 1971-1975
`B.S. conferred May, 1975
`Major: Bio logy
`M inor: Chem istry
`
`FELLOWSHIPS
`
`1979-1983
`
`1975-1979
`
`Postdoctoral Fellow, Division of Clinical Pharmacology, Department of
`Medicine, Advisor, F. Murad, M .D., Ph.D. (1998 Noble Laureate in
`Physiology or Medicine)
`1981-1983
`Stanford University, Palo Alto, California.
`1979-1981
`University of Virginia, Charlottesville, Virginia.
`
`Department of Anatomy, Thomas Jefferson University, Philadelphia,
`Pennsylvania; Advisor, K Chepenik, Ph.D.
`1976-1979
`NIH Predoctoral Fellow.
`1975-1976
`Foederer Predoctoral Fellow
`
`Bausch Health Ireland Exhibit 2030, Page 1 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`CLINICAL TRAINING
`1988-1990
`
`1987-1988
`
`Curriculum Vitae: Scott A. Waldman
`
`
`Resident, Department of Medicine, Stanford University Hospital, Palo
`Alto, California.
`Intern, Department of Medicine, Stanford University Hospital, Palo Alto,
`California.
`CERTIFICATION AND LICENSURE
`1994
`Diplomate of the American Board of Clinical Pharmacology.
`1991
`Physicians and Surgeons Certificate, Licensure by the State of Pennsylvania,
`Medical License.
`Diplomate, American Board of Internal Medicine, September 12, 1990
`(recertified 2000).
`Physicians and Surgeons Certificate, Licensure by the State of California.
`1988-1990
`Diplomate, National Board of Medical Examiners.
`1988
`FACULTY APPOINTMENTS
`Xuzhou Cancer Hospital, Xuzhou, China
`05/21/2017-05/21/2020-Visiting Professor
`University of Delaware, School of Health Sciences
`06/01/2012-present- Adjunct Professor
`Thomas Jefferson University, Philadelphia, Pennsylvania
`2022-present Chair, Department of Pharmacology, Physiology and Cancer Biology.
`2011-2015 Director, Jefferson Center for Individualized Medicine.
`2010-2016 Vice President, Clinical and Translational Research, Thomas Jefferson
`University.
`2010-2016 Associate Dean, Clinical and Translational Sciences, Jefferson Medical
`College.
`Chair, Department of Pharmacology and Experimental Therapeutics.
`2005-2022
`1999-present Tenure granted.
`1998-present Samuel M.V. Hamilton Professor of Medicine.
`1997-present Director, Division of Clinical Pharmacology, Department of Medicine.
`1996-1997
`Associate Director of Clinical Trials, Office of Scientific Affairs.
`1993-1998
`Associate Professor of Medicine, Division of Clinical Pharmacology.
`1993-1998
`Associate Professor of Biochemistry and Molecular Pharmacology.
`1991-present Graduate Faculty.
`1990-1993
`Assistant Professor of Medicine, Division of Clinical Pharmacology.
`1990-1993
`Assistant Professor of Pharmacology.
`Veterans Administration Medical Center, Palo Alto, California
`1983-1990
`Staff Pharmacologist.
`CLINICAL APPOINTMENTS
`1991-present
`Attending Physician, Thomas Jefferson University Hospital, Philadelphia,
`Pennsylvania.
`Medical Director, Clinical Research Unit, Thomas Jefferson University
`Hospital, Philadelphia, Pennsylvania.
`
`1990
`
`1991-1997
`
`
`
`
`
`
`
`Page 2
`
`Bausch Health Ireland Exhibit 2030, Page 2 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`2001-2005
`
`1997
`
`Curriculum Vitae: Scott A. Waldman
`
`
`TEACHING ACTIVITIES
`Thomas Jefferson University
`2007-present Lecturer, Advanced cellular and Molecular Immunology (IM605),
`Department of Microbiology and Immunology, (2 lecture hours).
`2004-present Lecturer, Molecular Pharmacology (PR680), Department of Biochemistry
`and Structural Biology, (1.5 lecture hours).
`2002-present Lecturer, Immunity, Infection and Disease (preclinical microbiology and
`immunology), Department of Microbiology and Immunology, (2 lecture
`hours).
`2001-present Lecturer, Protein Structure and Function, Department of Biochemistry and
`Molecular Pharmacology (3 lecture hours).
`Co-Director, Medical Pharmacology (PR 200) section of Foundations in
`Clinical Medicine (coordinate 36 lecture hours).
`2000-present Director, Masters Programs in Pharmacology: Human Investigation Track,
`Department of Biochemistry and Molecular Pharmacology.
`2000-present Program Director, NIH K30 Curriculum in Human Investigation.
`1997-present Program Director, NIH Training Program in Translational Research for
`Summer Medical Students.
`1997-present Director, MD-PhD Program.
`1997-2000
`Co-Director, Case Studies in Clinical Pharmacology (PR 760), Department
`of Biochemistry and Molecular Pharmacology (coordinate 24 lecture
`hours).
`Director, Clinical Pharmacology and Therapeutics (PR 401 (coordinate 60
`lecture hours).
`1996-present Program Director, NIH Postdoctoral Training Program in Clinical
`Pharmacology.
`1996-present Director, Masters Programs in Pharmacology: Clinical Pharmacology Track,
`Department of Biochemistry and Molecular Pharmacology.
`1995-1997 Director, Principles of Clinical Pharmacology (PR 525), Department of
`Biochemistry and Molecular Pharmacology (coordinate 45 lecture hours).
`1994-present Lecturer, Principles of Clinical Pharmacology (PR 525), Department of
`Biochemistry and Molecular Pharmacology (6 lecture hours).
`1994-present Director, Masters Program in Pharmacology: Clinical Scientist Track,
`Department of Biochemistry and Molecular Pharmacology .
`1994-1997 Director, General Pharmacology (PR 522), Department of Biochemistry
`and Molecular Pharmacology (45 lecture hours).
`1994-present Lecturer, General Pharmacology (PR 522), Department of Biochemistry
`and Molecular Pharmacology (3 lecture hours).
`1993-present Lecturer, Molecular Pharmacology (PR670), Department of Biochemistry
`and Molecular Pharmacology (3 lecture hours).
`1991, 1992 Medicine Grand Rounds, VA Hospital, Wilmington, Delaware (1 lecture
`hours).
`1991, 1992 Medicine House Staff Lecture Series (1 lecture hour).
`1991-1994
`Instructor, Introduction To Clinical Medicine And Physical Diagnosis,
`Department of Medicine (6 contact hours).
`Lecturer, Clinical Pharmacology and Therapeutics (PR 401), Department of
`Biochemistry and Molecular Pharmacology (4 lecture hours).
`
`1991-2000
`
`
`
`
`
`
`
`Page 3
`
`Bausch Health Ireland Exhibit 2030, Page 3 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`Curriculum Vitae: Scott A. Waldman
`
`
`1987
`
`1978
`
`1977
`
`1977
`
`1976
`
`1991-present Lecturer, Medical Pharmacology (PR 200), Department of Pharmacology
`(3 lecture hours).
`Invited Lecturer, graduate course in renal physiology, Department of
`Physiology.
`Student Instructor, course in transmembrane signaling and information
`cascades (Professor K.P. Chepenik), Department of Anatomy.
`Student Instructor, Neuroanatomy, (Professor Norman Moskowitz),
`Daniel Baugh Institute of Anatomy.
`Prosector and Student Instructor, Gross Anatomy (Professor Jay Shea),
`Daniel Baugh Institute of Anatomy.
`Student Instructor, Histology (Professor August Epple), Daniel Baugh
`Institute of Anatomy.
`Stanford University
`1990
`Instructor, Introduction To Clinical Medicine And Physical Diagnosis
`(Christopher Snow, M.D.), Department of Medicine.
`Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department
`of Physiology.
`
`1990
`
`PRESENTATIONS
`09/22
`
`10/19
`
`02/19
`
`09/18
`
`07/18
`
`05/18
`
`03/18
`
`2/18
`
`1/18
`
`1/18
`
`1/18
`
`Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention.
`Translational Advances in Cancer Prevention Agent Development
`(TACPAD). NCI. September 7-9, 2022.
`Translating GUCY2C as a target for colorectal cancer chemoprevention.
`Bench to Bedside and Beyond: Translational Research to Real World
`Evidence. Janssen, Titusville, NJ, October 8, 2019.
`Paracrine hormone hypothesis of colorectal cancer. What every doctor
`should know: A general medical update. Vail, CO, February 3-6, 2019.
`Paracrine hormone hypothesis of colorectal cancer. 10th International
`Conference on the Biology, Chemistry and Therapeutic Applications of
`Nitric Oxide, Oxford, UK, September 16-20, 2018.
`Paracrine hormone hypothesis of colorectal cancer. Ironwood
`Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018.
`Paracrine hormone hypothesis of colorectal cancer. Division of Clinical
`Pharmacology, Departments of Medicine and Pharmacology, Johns
`Hopkins University, Baltimore, MD, May 23, 2018.
`Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M.
`Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical
`College, New York, March 13, 2018.
`Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting,
`Dallas, TX, February 23-24, 2018.
`PharmGKB Future Directions, Expert Panel, NHGRI PharmGKB Future
`Directions, Bethesda, MD, January 23, 2018.
`GUCY2C ligands to treat visceral pain. Key Opinion Leaders Meeting,
`Synergy Pharmaceuticals, New York, New York, January 19-20, 2018.
`Hormone suppression silencing GUCY2C is required for colorectal cancer.
`Department of Anatomy, Cell Biology, and Pathology, Thomas Jefferson
`University, Philadelphia, PA, January 19, 2018.
`
`
`
`
`
`
`
`Page 4
`
`Bausch Health Ireland Exhibit 2030, Page 4 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`12/17
`
`11/17
`
`10/17
`
`07/17
`
`06/17
`
`06/17
`
`05/17
`
`05/17
`
`05/17
`
`05/17
`
`04/17
`
`03/17
`
`02/17
`
`02/17
`
`01/17
`
`01/17
`
`Curriculum Vitae: Scott A. Waldman
`
`Hormone suppression silencing GUCY2C is required for colorectal cancer.
`Visiting Professor, GI Core Center, Division of Gastroenterology &
`Hepatology, Department of Medicine, Johns Hopkins University,
`Baltimore, MD, December 19, 2017.
`Paracrine hormone hypothesis of colorectal cancer. Visiting Professor,
`Department of Microbiology and Immunology, Drexel University,
`Philadelphia, PA, November 29, 2017.
`GUCY2C ligands to treat chronic constipation syndromes. Synergy
`Satellite Meeting, American College of Gastroenterology National
`Meeting, Orlando, FL, October 17, 2017.
`GUCY2C ligands to treat visceral pain. Synergy Satellite Meeting,
`American Neurogastroenterology and Motility Society, New York, New
`York, August 3, 2017.
`GUCY2C ligands to treat visceral pain. Synergy Advisory Meeting,
`Washington, D.C., June 16-17, 2017.
`Guanylate cyclase at the intersection of colorectal cancer and obesity.
`8th International Conference on cGMP. cGMP: Generators, Effectors, and
`Therapeutic Implications, June 22-225, Bamburg, Germany.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Grand Rounds, Abington Health System, Philadelphia, PA, May
`24, 2017.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Grand Rounds, Xuzhou Medical University, Xuzhou, China, May
`24, 2017.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Grand Rounds, Wuxi Second People’s Hospital, Wuxi, China,
`May 19, 2017.
`Paracrine hormone hypothesis of colorectal cancer. Visiting Professor,
`Department of Cell Biology and Pharmacology, Florida International
`University, Miami, Florida, May 2-3, 2017.
`Advancing immune-oncology for gastrointestinal cancers. ICV
`Philadelphia: Healthcare Innovation Forum, Philadelphia, PA, April 25,
`2017.
`Paracrine hormone hypothesis of colorectal cancer. Visiting Professor,
`Department of Biomedical Engineering, University of Delaware, Newark,
`DE, March 27, 2017.
`GUCY2C ligands to treat chronic constipation syndromes. Synergy
`Advisory Meeting, Orlando, FL, February 18, 2017.
`Advancing immune-oncology for gastrointestinal cancers. What every
`doctor should know: A general medical update. British Columbia,
`February 5-10, 2017.
`Paracrine hormone hypothesis of colorectal cancer. American Medical
`School Pharmacology Chairs, Oaxaca, Mexico, January 25-29, 2017.
`Colorectal cancer prevention by GUCY2C signaling. Fox Chase Cancer
`Center, Philadelphia, PA, January 24, 2017.
`
`
`
`
`
`
`
`Page 5
`
`Bausch Health Ireland Exhibit 2030, Page 5 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`11/16
`
`10/16
`
`10/16
`
`09/16
`
`09/16
`
`09/16
`
`08/16
`
`04/16
`
`12/15
`
`12/15
`
`10/15
`
`09/15
`
`08/15
`
`07/15
`
`07/15
`
`06/15
`
`06/15
`
`05/15
`
`04/15
`
`Curriculum Vitae: Scott A. Waldman
`
`
`Advancements in cancer research through immunotherapy, American
`Cancer Society Cancer Action Network, Philadelphia, PA, November 2,
`2016.
`Immuno-oncology approaches to GI malignancies. Kimmel Cancer
`Center Retreat, Philadelphia, PA, September 14, 2016.
`GUCY2C and colon cancer management. Philadelphia College of
`Osteopathic Medicine, October 5, 2016.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Annual Nursing Oncology Conference, Philadelphia, PA,
`September 21, 2016.
`GUCY2C ligand pharmacology and physiology. Plecanatide Advisory
`Board Meeting (Chair), Chicago, IL, September 17, 2016.
`Paracrine hormone hypothesis of colorectal cancer. NCI-Ironwood
`Program Review, Boston, MA, September 1, 2016.
`GUCY2C ligand pharmacology and physiology. American
`Neurogastroenterology and Motility Society. Plecanatide Advisory Board
`Meeting (Chair), San Francisco, CA, August 28, 2016.
`GUCY2C ligand pharmacology and physiology. Plecanatide Advisory
`Board Meeting (Chair), Chicago, IL, April 29-30, 2016.
`Paracrine hormone hypothesis of colorectal cancer. Penn State Hershey
`Cancer Center, Hershey, PA, December 9-10, 2015.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Macrogenics, Rockville, MD, December 3, 2015.
`GUCY2C and colon cancer management. Philadelphia College of
`Osteopathic Medicine, October 09, 2015.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Pfizer Science Day Keynote Address, Pfizer, Collegeville, PA,
`September 1, 2015.
`Paracrine hormone hypothesis of colorectal cancer. Fox Chase Cancer
`Center, Philadelphia, PA, August 25, 2015.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. The Commonwealth Medical College, Scranton , PA, July 31,
`2015.
`Paracrine hormone hypothesis of colorectal cancer. Molecular
`Therapeutics of Cancer Research Conference, Tufts University, July 12-15-
`21, Medford, MA.
`Paracrine hormone hypothesis of colorectal cancer. Allergan, June 29,
`2015.
`Paracrine hormone hypothesis of colorectal cancer. 7th International
`Conference on cGMP. cGMP: Generators, Effectors, and Therapeutic
`Implications, June 19-21, Trier, Germany.
`Paracrine hormone hypothesis of colorectal cancer. University of Virginia
`Cancer Center, May 1, 2015.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Reynold Spector Award in Clinical Pharmacology Lecture,
`American Society of Pharmacology and Experimental Therapeutics,
`Boston, April 31, 2015.
`
`
`
`
`
`
`
`Page 6
`
`Bausch Health Ireland Exhibit 2030, Page 6 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`03/15
`
`02/15
`
`011/14
`
`10/14
`
`05/14
`
`04/14
`
`10/13
`
`08/13
`
`06/13
`
`06/13
`
`06/13
`
`02/13
`
`02/13
`
`12/12
`
`10/12
`
`10/12
`
`04/12
`
`03/12
`
`Curriculum Vitae: Scott A. Waldman
`
`
`Presenting Your Work. American Society for Clinical Pharmacology and
`Therapeutics, New Orleans, March 4, 2015
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Paoli Medical Institute, Paoli, PA, February 24, 2015.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Cooper Medical School of Rowan University, NJ, November 24,
`2014.
`GUCY2C and colon cancer management. Philadelphia College of
`Osteopathic Medicine, October 10, 2014.
`The Case for Standards in the Biological Sciences. Expert Panel. New
`York Biotechnology Conference, New York, May 14-15, 2014.
`GUCY2C at the intersection of obesity and colorectal cancer. Annual
`ASPET Meeting, San Diego, CA, April 25-20, 2014.
`GUCY2C and colon cancer management. Philadelphia College of
`Osteopathic Medicine, October 12, 2013.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Keynote Speaker, Northeast Regional Idea Conference,
`University of Delaware, Newark, DE, August 15-16, 2013.
`GUCY2C at the intersection of obesity and colorectal cancer. 6th
`International Meeting on cGMP, Erfurt, Germany, June 28-30, 2013.
`GUCY2C at the intersection of obesity and colorectal cancer. Eighth
`ISABS Conference on Forensic, Anthropologic and Medical Genetics and
`Mayo Clinic Lectures on Translational Medicine, Split, Croatia, June 24-28,
`2013.
`Training Programs for Clinician Scientists. Expanding Clincial Training
`Opportunities for Biomedical Scientists, Cornell Unviersity, New York, June
`11-12, 2013.
`GUCY2C at the intersection of obesity and colorectal cancer. Symposium
`Particulate GCs in the cardiovascular system and beyond at the 92nd
`Annual Meeting of the German Physiological Society, Heidelberg,
`Germany, March 2-5, 2013.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Nemours-AI DuPont Hospital for Children, Wilmington, DE,
`February 11, 2013.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. LaSalle University, Philadelphia, PA December 3, 2012.
`GUCY2C and colon cancer management. Philadelphia College of
`Osteopathic Medicine, October 10, 2012.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Jefferson Biomedical Research Forum, Philadelphia, PA October
`3, 2012.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Department of Biochemistry and Center for Molecular
`Medicine, George Washington Unviersity, Washington, D.C., April 16,
`2012.
`Occult tumor burden contributes to racial disparities in stage-specific
`colorectal cancer outcomes. Consensus Conference on Strategies for
`
`
`
`
`
`
`
`Page 7
`
`Bausch Health Ireland Exhibit 2030, Page 7 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`Curriculum Vitae: Scott A. Waldman
`
`
`Screening Colorectal Cancer in the Military, Orlando, FL, March 19-20,
`2012.
`Translational Medicine: From Knowledge Generation To Healthcare
`Delivery. Rawls-Palmer Progress in Medicine Award Presentation. ASCPT
`Annual Meeting, National Harbor, Maryland, March 16, 2012.
`Occult tumor burden contributes to racial disparities in stage-specific
`colorectal cancer outcomes. NCI Symposium Cancer Health Disparities,
`Bethesda MD, July 12-15, 2011.
`Occult tumor burden contributes to racial disparities in stage-specific
`colorectal cancer outcomes. Keystone Symposium Changing Landscape
`of the Cancer Genome, Boston, MA, June 20-25, 2011.
`Molecular staging in colorectal cancer. Lankenau Institute for Medical
`Research, Lankenau, PA, April XYZ, 2011.
`Transforming healthcare: Biosensors and wellness maintenance.
`Keynote address, DARPA-FDA Workshop: Expanding in vivo biomarker
`detection devices. Crystal City, Virginia, February 8-9, 2011.
`Biomarkers and sample sites. Panel Leader, DARPA-FDA Workshop:
`Expanding in vivo biomarker detection devices. Crystal City, Virginia,
`February 8-9, 2011.
`Molecular staging in colorectal cancer. Women & Childrens Health
`Research Conference, Delaware Health Sciences Alliance, University of
`Delaware, December 10, 2010.
`Molecular staging in colorectal cancer. Karmanos Cancer Center, Wayne
`State University, Detroit, MI, December 9, 2010.
`GUCY2C and colon cancer management. Philadelphia College of
`Osteopathic Medicine, October 6, 2010.
`Molecular staging in colorectal cancer. Sadie Gerson Distinguished
`Scholar Award Program, University of Pittsburgh, September 17, 2010.
`The paracrine hormone hypothesis of colon cancer. Fundacion Ramon
`Areces International Symposium New Advances in Colorectal Cancer
`Research, May 27-28 2010.
`Molecular staging in colorectal cancer. AI DuPont-Nemours Childrens
`Hospital, Wilmington, DE, December 14, 2009.
`Molecular staging in colorectal cancer. Ironwood Pharmaceuticals,
`Cambridge, MA, December 11, 2009.
`GUCY2C in lymph nodes predicts time to recurrence and disease-free
`survival in pN0 colorectal cancer. Department of Anatomy, Cell and
`Developmental Biology and Pathology, Thomas Jefferson University,
`Philadelphia, PA, November 4, 2009.
`GUCY2C biology and secretory regulation in intestine. CombiMab,
`Wilmington, DE.
`GUCY2C in lymph nodes predicts time to recurrence and disease-free
`survival in pN0 colorectal cancer. International Society for Applied
`Biological Sciences, Split, Croatia, June 1-5, 2009.
`Molecular staging in colorectal cancer. ASCPT annual meeting,
`Washington, DC, March 17-21.
`
`03/12
`
`07/11
`
`06/11
`
`04/11
`
`02/11
`
`02/11
`
`12/10
`
`12/10
`
`10/10
`
`9/10
`
`5/10
`
`12/09
`
`12/09
`
`11/09
`
`09/09
`
`06/09
`
`03/09
`
`
`
`
`
`
`
`Page 8
`
`Bausch Health Ireland Exhibit 2030, Page 8 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`03/09
`
`02/09
`
`11/08
`
`11/08
`
`11/08
`
`09/08
`
`09/08
`
`08/08
`
`06/08
`
`05/08
`
`05/08
`
`02/08
`
`01/08
`
`01/08
`
`12/07
`
`10/07
`
`Curriculum Vitae: Scott A. Waldman
`
`
`MicroRNA as prognostic and predictive markers in cancer. ASCPT annual
`meeting, Washington, DC, March 17-21.
`GUCY2C in lymph nodes predicts time to recurrence and disease-free
`survival in pN0 colorectal cancer. National Press Club, Washington, D.C.,
`February 17, 2009.
`The paracrine hormone hypothesis of colorectal cancer. Department of
`Medicine, University of Iowa, Rapid City, Iowa, November 20, 2008.
`The paracrine hormone hypothesis of colorectal cancer. Lennox Black
`Prize for Excellence in Biomedical Research Symposium: Transformational
`Discoveries in Cancer. November 10-11, 2008, Philadelphia, PA.
`GUCY2C in lymph nodes predicts time to recurrence and disease-free
`survival in pN0 colorectal cancer. NCI Translational Science Meeting,
`November 14-16, Washington, DC.
`Occult metastases predict recurrence risk in patients with pN0 colorectal
`cancer. Biomarker Discovery Summit. September 29-October 1,
`Philadelphia, PA.
`Invited Speaker, Media Round Table, AACR Conference on Molecular
`Diagnostics in Cancer Drug Development, September 22-25, 2008,
`Philadelphia, PA.
`Development of novel vaccines for GI malignancies. Adam Snook, PhD,
`Invited Faculty, Advances In Cancer Vaccines, Boston, Canada, August 13-
`14, 2008.
`Molecular approaches to individualized management of cancer. ECOG,
`Boston, MA, June 29, 2008.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. Keynote Address, ISSX,
`Vienna, Austria, May 21, 2008.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. DiagnoCure,
`Westchester, PA, May 13, 2008.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. Annual Symposium:
`Colorectal Cancer, Thomas Jefferson University, Philadelphia, PA,
`February 29, 2008.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. Quest Diagnostics,
`Chantilly, VA, January 29, 2008.
`Development of novel vaccines for GI malignancies. Cancer
`Immunotherapeutic Division, GlaxoSmithKline, Montreal, Canada, January
`25, 2008.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. Nichols Institute,
`December 14, 2007.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. Philadelphia College of
`Osteopathic Medicine, October 10, 2007.
`
`
`
`
`
`
`
`Page 9
`
`Bausch Health Ireland Exhibit 2030, Page 9 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`10/07
`
`09/07
`
`08/07
`
`01/07
`
`01/07
`
`11/06
`
`11/06
`
`07/06
`
`06/06
`
`01/06
`
`12/05
`
`11/05
`
`10/05
`
`05/05
`
`05/05
`
`Curriculum Vitae: Scott A. Waldman
`
`
`At the intersection of epidemiology and cancer biology: Insights in colon
`carcinogenesis gained from studies of enterotoxigenesis. Kimmel Cancer
`Center Grand Rounds, Thomas Jefferson University, Philadelphia, PA
`October 1, 2007.
`Squaring The Curve. The Aging Revolution. Philadelphia, PA September
`26-27, 2007.
`MicroRNAs as clinical biomarkers in cancer: Implications for identifying
`novel therapeutic targets. Targeted Therapies in Cancer. Washington,
`D.C. August 22-24, 2007.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. Division of
`Gastroenterology, Thomas Jefferson University, Philadelphia, PA, June 22,
`2006.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. DiagnoCure,
`Philadelphia, PA, January 26, 2006.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. ECOG Semiannual
`Meeting, Miami, FL.
`At the intersection of epidemiology and cancer biology: Insights in colon
`carcinogenesis gained from studies of enterotoxigenesis. Interurban
`Clinical Club 194th Meeting, Philadelphia, PA July 26, 2007.
`At the intersection of epidemiology and cancer biology: Insights in colon
`carcinogenesis gained from studies of enterotoxigenesis. Kimmel Cancer
`Center Grand Rounds, Thomas Jefferson University, Philadelphia, PA July
`26, 2007.
`From bench to bedside and back again: Development of novel
`diagnostics and therapeutics for GI malignancies. Division of
`Gastroenterology, University of Pennsylvania, Philadelphia, PA, June 22,
`2006.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Division of Clinical Pharmacology,
`Vanderbilt University, Nashville, TN, January 10, 2006.
`At the intersection of epidemiology and cancer biology: Insights in colon
`carcinogenesis gained from studies of enterotoxigenesis. Mayo Clinic
`Comprehensive Cancer Center, Rochester, MN, December 8, 2005.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Pharmacology,
`University of Minnesota, Minneapolis, MN, November 11, 2005.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Invitrogen, San Diego, CA, October 27,
`2005.
`Quantitative aspects of the dose-response relationship. Division of
`Clinical Pharmacology, UCLA, Los Angeles, CA, May 10, 2005.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Division of Clinical Pharmacology,
`UCLA, Los Angeles, CA, May 10, 2005.
`
`
`
`
`
`
`
`Page 10
`
`Bausch Health Ireland Exhibit 2030, Page 10 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`05/05
`
`04/05
`
`02/05
`
`02/05
`
`01/05
`
`12/04
`
`12/04
`
`11/04
`
`11/04
`
`11/04
`
`11/04
`
`10/04
`
`10/04
`
`10/04
`
`Curriculum Vitae: Scott A. Waldman
`
`
`From bench to bedside and back again: Forward and reverse translation
`in GI malignancies. Division of Clinical Pharmacology, Mayo Clinic and
`Foundation, Rochester, MN, May 6, 2005.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Surgery Grand Rounds,
`Thomas Jefferson University, Philadelphia, PA, April 13, 2005.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Clinical Genomics, IBC Life Sciences,
`San Diego, CA, February 17-18, 2005.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Translational Research, Cambridge
`Health Institute, San Francisco, CA, February 8-9, 2005.
`Bacterial enterotoxins confer resistance to colon cancer. Pennsylvania
`Society of Colorectal Surgeons, Philadelphia, PA, January 14, 2005.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Grand Rounds, Department of
`Radiology, Thomas Jefferson University, Philadelphia, PA, December 7,
`2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. New Jersey Chapter of the American
`College of Surgeons, Parsippany, NJ, December 4, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Visiting Professor, Department of
`Immunology, Johns Hopkins School of Medicine, Baltimore, MD,
`November 12, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Grand Rounds, Department of
`Medicine, Thomas Jefferson University, Philadelphia, PA, November 11,
`2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Visiting Professor, Lankenau Research
`Institute, Wynnewood, PA, November 4, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Ventana Medical Systems, Inc., Tuscon,
`AZ, November 2, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Molecular Pathology Institute, LabCorp
`Inc., Research Triangle Park, N.C, October 19, 2004.
`Bacterial enterotoxins confer resistance to colon cancer. Kimmel Cancer
`Center Grand Rounds, Thomas Jefferson University, Philadelphia, October
`13, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Keynote Address, Mauvernay
`Symposium and Awards, Tulane University, New Orleans, October 8,
`2004.
`
`
`
`
`
`
`
`Page 11
`
`Bausch Health Ireland Exhibit 2030, Page 11 of 71
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`10/04
`
`09/04
`
`7/04
`
`7/04
`
`5/04
`
`2/04
`
`02/04
`
`11/03
`
`09/03
`
`08/03
`
`07/03
`
`06/03
`
`06/03
`
`06/03
`
`04/03
`
`Curriculum Vitae: Scott A. Waldman
`
`
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Anatomy, Philadelphia
`College of Osteopathic Medicine, Pennsylvania, October 5, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Medicine Grand
`Rounds, Paoli Memorial Hospital, Paoli, Pennsylvania, September 29,
`2004.
`Bacterial enterotoxins confer resistance to colon cancer. Louisiana
`Cancer Research Consortium Seminar, Louisiana State and Tulane
`Universities, New Orleans, Louisiana, July 15, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Medicine Grand
`Rounds, Tulane University, New Orleans, Louisiana, July 14, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Medicine Grand
`Rounds, University of Indiana, Indianapolis, Indiana, May 12, 2004.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Pharmacology and
`Integrative Biology, University of Texas Houston, February 23, 2004,
`Houston, Texas.
`From bench to bedside: Development of novel diagnostics and
`therapeutics for GI malignancies. Department of Surgery, Thomas
`Jefferson University, February 18, 2004, Philadelphia, PA.
`Novel diagnostics and therapeutics for GI malignancies. Kimmel Cancer
`Center Staff Seminar, Thomas Jefferson University, November 9,
`Philadelphia, PA.
`Guanylyl cyclase is a marker and target for colorectal cancer.
`Translational Research Conference, Helen Graham Cancer Center,
`Christiana Medical Center, Christiana Delaware. September 15,
`Philadelphia
`Guanylyl cyclase is a marker and target for colorectal cancer. Oncology
`Grand Rounds, Thomas Jefferson University, June 23, Philadelphia.
`Interaction of antihistamines and antidepressants. Antihistamines And
`Cognitive Function Advisory Board, Aventis. July 24-25, New York.
`Guanylyl cyclase is a marker and target for colorectal cancer.
`Translational Opportunities. Kimmel Cancer Center, Thomas Jefferson
`University, June 23, Philadelphia.
`Guanylyl cyclase C is a molecular marker for staging patients with
`colorectal cancer. National Surgical Adjuvant Breast and Bowel Project
`(NSABP), Orlando.
`Bacterial enterotoxins confer resistance to colon cancer. First
`International Confer